Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2016

Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2016
Published Jul 20, 2016
45 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2016, provides an overview of the Functional (Non Ulcer) Dyspepsia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Functional (Non Ulcer) Dyspepsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Functional (Non Ulcer) Dyspepsia and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Functional (Non Ulcer) Dyspepsia
- The report reviews pipeline therapeutics for Functional (Non Ulcer) Dyspepsia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Functional (Non Ulcer) Dyspepsia therapeutics and enlists all their major and minor projects
- The report assesses Functional (Non Ulcer) Dyspepsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Functional (Non Ulcer) Dyspepsia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Functional (Non Ulcer) Dyspepsia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline

  
Source:
Document ID
GMDHC8251IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Functional (Non Ulcer) Dyspepsia Overview61
Therapeutics Development72
  Pipeline Products for Functional (Non Ulcer) Dyspepsia Overview71
  Pipeline Products for Functional (Non Ulcer) Dyspepsia Comparative Analysis81
Functional (Non Ulcer) Dyspepsia Therapeutics under Development by Companies91
Functional (Non Ulcer) Dyspepsia Therapeutics under Investigation by Universities/Institutes101
Functional (Non Ulcer) Dyspepsia Pipeline Products Glance113
  Late Stage Products111
  Clinical Stage Products121
  Early Stage Products131
Functional (Non Ulcer) Dyspepsia Products under Development by Companies141
Functional (Non Ulcer) Dyspepsia Products under Investigation by Universities/Institutes151
Functional (Non Ulcer) Dyspepsia Companies Involved in Therapeutics Development165
  Ironwood Pharmaceuticals, Inc.161
  RaQualia Pharma Inc.171
  Yuhan Corporation181
  Zensun (Shanghai) Sci &Tech Co., Ltd.191
  Zeria Pharmaceutical Co., Ltd.201
Functional (Non Ulcer) Dyspepsia Therapeutics Assessment218
  Assessment by Monotherapy Products211
  Assessment by Target222
  Assessment by Mechanism of Action242
  Assessment by Route of Administration261
  Assessment by Molecule Type272
Drug Profiles2911
  5-BIOP Drug Profile291
  acotiamide hydrochloride Drug Profile302
  LT-4005 Drug Profile321
  recanaclotide Drug Profile332
  RQ-00000010 Drug Profile352
  RQ-00201894 Drug Profile371
  YH-12852 Drug Profile381
  ZS-07 Drug Profile391
Functional (Non Ulcer) Dyspepsia Dormant Projects401
Functional (Non Ulcer) Dyspepsia Discontinued Products411
Functional (Non Ulcer) Dyspepsia Product Development Milestones422
  Featured News &Press Releases421
    Oct 20, 2014: Ironwood Presents IW-9179 Phase IIa Data at American College of Gastroenterology 2014 Annual Scientific Meeting421
    Mar 25, 2013: Zeria Pharma Receives Approval For Acofide In Japan For Treating Functional Dyspepsia421
    Feb 29, 2012: RaQualia Pharma Receives MHRA Approval To Initiate First-In-Human Study For 5-HT4 Partial Agonist RQ-00000010431
Appendix442
  Methodology441
  Coverage441
  Secondary Research441
  Primary Research441
  Expert Panel Validation441
  Contact Us441
  Disclaimer451

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Functional-Non-Ulcer-Dyspepsia-Pipeline-Review-H2-2016-2088-16225>
  
APA:
Global Markets Direct - Market Research. (2016). Functional (Non Ulcer) Dyspepsia - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Functional-Non-Ulcer-Dyspepsia-Pipeline-Review-H2-2016-2088-16225>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.